6-Nitrodopamine potentiates contractions of rat isolated vas deferens induced by noradrenaline, adrenaline, dopamine and electric field stimulation

• DOI: 10.1007/s00210-023-02478-6
• Publication Date: 2023-04-04T12:19:23Z
• Authors: José Britto-Júnior; Antonio Tiago Lima; Rafael Campos; Alexandre Asturia...; Gustavo Duarte Me...; Luiza P. Ferreira...; Adriano Fregonesi; André Sampaio Pupo; Edson Antunes; Gilberto De Nucci
• Keywords: Atropine; Male; 0303 health sciences; Reserpine; Epinephrine; Dopamine; Indomethacin; Synergism; Electric Stimulation; 3. Good health; Rats; Receptors, Adrenergic; Norepinephrine; 03 medical and health sciences; Vas Deferens; Catecholamines; Idazoxan; Animals; Nitrocatecholamines; Muscle Contraction

Abstract 6-nitrodopamine (6-ND) is a novel endogenous catecholamine that is released from rat isolated vas deferens, and it has been characterized as a major modulator of the contractility of rat isolated epididymal vas deferens (RIEVD). Drugs such as tricyclic antidepressants, a1 and b1b2 adrenoceptor blockers, act as selective antagonists of the 6-ND receptor in the RIEVD. In the rat isolated atria, 6-ND has a potent positive chronotropic action and causes remarkable potentiation of the positive chronotropic effects induced by dopamine, noradrenaline, and adrenaline. Here it was investigated whether 6-ND interacts with the classical catecholamines in the rat isolated vas deferens. Incubation with 6-ND (0.1 and 1nM; 30min) caused no contractions in the RIEVD but provoked significant leftward shifts in the concentration-response curves to noradrenaline, adrenaline, and dopamine. Pre-incubation of the RIEVD with 6-ND (1nM), potentiated the contractions induced by electric-field stimulation (EFS), whereas pre-incubation with 1nM of dopamine, noradrenaline or adrenaline, did not affect EFS-induced contractions. In tetrodotoxin (1mM) pre-treated (30 min) RIEVD, pre-incubation with 6-ND (0.1nM) did not caused leftward shifts in the concentration-dependent contractions induced by noradrenaline, adrenaline, or dopamine. Pre-incubation of the RIEVD with the α2A-adrenoceptor antagonist idazoxan (30 min, 10 nM) did not affect dopamine, noradrenaline, adrenaline, and EFS-induced contractions. However, when idazoxan (10nM) and 6-ND (0.1nM) were simultaneously pre-incubated (30 min), a significant potentiation of the EFS-induced contractions of the RIEVD was observed. 6-nitrodopamine causes remarkable potentiation of dopamine, noradrenaline, and adrenaline contractions on the RIEVD, due to activation of adrenergic terminals, possibly via pre-synaptic adrenoceptors.